Michael Wang, MD
Professor, Department of Lymphoma-Myeloma Division of Cancer Medicine, MD Anderson Cancer CenterMichael Wang, MD, is a professor in the department of lymphoma and myeloma, division of cancer medicine, at MD Anderson Cancer Center in Houston, Texas. He is also the current director of the Mantle Cell Lymphoma Program of Excellence and co-director of clinical trials at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and has presented his work at meetings nationally and internationally. His clinical research on the Bruton’s tyrosine kinase inhibitor ibrutinib was published in the New England Journal of Medicine in 2013. He currently acts as national principal investigator (PI) of the multisite international phase 5 registration trial for ibrutinib in mantle cell lymphoma, and also serves as the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
Dr. Wang is the founder, current director and PI of The Michael Wang Laboratory research program at MD Anderson, which aims to elucidate the mechanisms underlying therapeutic resistance in B-cell lymphomas and to translate those findings to the clinic to improve patient outcomes.
